Spectranetics (Nasdaq: SPNC) is expected to report Q4 earnings on Feb. 21. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Spectranetics's revenues will grow 9.4% and EPS will wither -25.0%.

The average estimate for revenue is $35.6 million. On the bottom line, the average EPS estimate is $0.03.

Revenue details
 Last quarter, Spectranetics notched revenue of $35.2 million. GAAP reported sales were 9.7% higher than the prior-year quarter's $32.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, EPS came in at $0.03. GAAP EPS of $0.03 for Q3 were much higher than the prior-year quarter's $0.00 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 72.7%, 30 basis points worse than the prior-year quarter. Operating margin was 3.1%, about the same as the prior-year quarter. Net margin was 2.6%, 230 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $138.9 million. The average EPS estimate is $0.07.

Investor sentiment
 The stock has a one-star rating (out of five) at Motley Fool CAPS, with 152 members out of 171 rating the stock outperform, and 19 members rating it underperform. Among 38 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 31 give Spectranetics a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Spectranetics is outperform, with an average price target of $14.86.

Is Spectranetics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.